Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at ...

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Lack of a skilled talent pool, and slow logistics operations are among the major challenges that could discourage India’s ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...